Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02231008 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS
A Phase 2 study of Smith-Magenis Syndrome and Circadian, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 4
- Study locations
NCT02231008: Completed Phase 2 study of Smith-Magenis Syndrome and Circadian, sponsored by Vanda Pharmaceuticals.
NCT02231008 is a Phase 2 study of Smith-Magenis Syndrome and Circadian that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 49 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02231008, a Phase 2 study of Smith-Magenis Syndrome and Circadian, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.
Conditions Studied
Interventions
- DRUG placebo
- DRUG tasimelteon
Study Locations (4)
Maryland
- - Baltimore
- - Chevy Chase
California
- - Santa Monica
Texas
- - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2015-09 |
| Est. Completion | 2022-01 |
| Phase | Phase 2 |
What the finished NCT02231008 record still lists
NCT02231008 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Smith-Magenis Syndrome appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02231008 reports a single indexed study location in Maryland, California, Texas.
Frequently Asked Questions
What is clinical trial NCT02231008 about?
NCT02231008 is a clinical study titled "Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS". The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.
What is the current status of trial NCT02231008?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2015-09. Estimated completion is 2022-01.
What conditions does trial NCT02231008 study?
This clinical trial studies the following conditions: Smith-Magenis Syndrome, Circadian.
What interventions are being tested in trial NCT02231008?
The interventions under investigation include: placebo (DRUG), tasimelteon (DRUG).
Who is sponsoring clinical trial NCT02231008?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02231008 being conducted?
This trial has 4 study locations across California, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smith-Magenis Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02231008's enrollment target sits among peer trials
49 1261st of 2000 higher than 736 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia